Drug Profile
Recombinant erythropoietin - XTL
Alternative Names: EPO - XTL; rHuEPO - XTLLatest Information Update: 22 May 2023
Price :
$50
*
At a glance
- Originator Bio-GAL
- Developer XTL Biopharmaceuticals
- Class Antianaemics; Polyethylene glycols; Recombinant erythropoietins; Recombinant fusion proteins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Multiple myeloma
Most Recent Events
- 31 Dec 2022 Discontinued - Phase-I for Multiple myeloma in Israel (Parenteral)
- 28 Jun 2019 No recent reports of development identified for phase-I development in Multiple-myeloma in Israel (Parenteral)
- 02 May 2016 Phase-I clinical trials in Multiple myeloma in Israel (Parenteral)